GHK-Cu is a copper-binding peptide the body makes naturally and loses with age, studied for skin, hair, and tissue repair.
This page covers what it is and does, why someone would consider it, where the evidence stands, our view on using it, and how it fits a targeted plan. It also covers why, as with any injected peptide, the source matters as much as the molecule.
Reviewed by Dr. David Oliak, board-certified surgeon
Updated August 2026
GHK-Cu is a copper-binding peptide the body produces naturally — present in plasma, saliva, and urine — whose levels decline with age, falling roughly 60 percent between age 20 and age 60.
It was first identified by the researcher Loren Pickart in the 1970s as a factor in human plasma, and has been studied since for skin quality, hair, and tissue repair.
GHK-Cu is used to support skin quality, hair, and tissue repair. The reason to consider it is replenishment: the body's own GHK-Cu declines substantially with age. Restoring it aims to support the repair and remodeling processes it normally drives, rather than introducing a foreign compound.
That is the goal patients are usually after — better skin quality and firmness, support for thinning hair, and improved tissue repair — in someone whose own levels have fallen.
In studies GHK-Cu has been associated with collagen and elastin production, with skin firmness and hydration, with hair follicle support, and with wound healing and reduced inflammation. These are the reported and studied applications; they are not established, FDA-approved indications.
It is given by subcutaneous injection for systemic effect, and is also used topically in skincare, a separate application from the injectable therapy described here.
GHK-Cu can be delivered in more than one way, and the route matters. It is given by subcutaneous injection for systemic effect, and it is also used topically on the skin, where the strongest evidence lies.
A third approach, topical application with microneedling, can drive higher concentrations into the skin locally than a systemic injection achieves, which is of particular interest for hair and skin.
GHK-Cu binds and delivers copper, a cofactor in a range of repair and remodeling processes. In laboratory and animal studies it has been associated with increased collagen, elastin, and other components of the skin matrix.
It has also been associated with follicle support, including effects on the 5-alpha-reductase pathway relevant to hair, and with tissue repair, new blood-vessel formation, and reduced inflammation.
In [gene-expression analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/), GHK has been reported to influence a large share of human genes, on the order of a third of the genome, increasing the activity of some and reducing others.
This picture is drawn largely from preclinical and topical research; it has not been established for injectable, systemic use in human trials.
Where the evidence stands for GHK-Cu.
The evidence is strongest in laboratory and skin research, with more limited human data for injectable, systemic use. In our own practice, GHK-Cu is one of our more popular peptides: most patients experience skin and hair benefits, and it is generally well liked.
Our verdict: GHK-Cu occurs naturally, declines with age, and has a long research record, including gene-expression work showing broad effects. Replenishing it is therefore a lower-bar decision than introducing a novel compound.
Most of that evidence is topical rather than injectable, which is exactly why we pay attention to delivery: applied locally, including with microneedling, GHK-Cu reaches higher concentrations in the skin than a systemic injection.
In our practice it is a popular, well-liked peptide, and most patients see skin and hair benefits. We prescribe it in cycles with copper monitoring, from an accountable source, not an unverified online product, particularly for an injected peptide that also delivers copper.
And we use it the way we use any peptide: as one targeted tool, chosen for a defined goal and matched to the patient, within a plan we have thought through. It is not a single vial used in isolation.
— Dr. David Oliak, board-certified physician and surgeon
GHK-Cu is distinctive among the peptides we prescribe because it delivers copper, and copper requires attention. It is roughly one-third copper by weight, so it carries a meaningful copper load. The body normally regulates copper absorption in the gut, and an injection bypasses that control.
For this reason, GHK-Cu is used in cycles rather than continuously, and longer-term use is monitored with periodic blood testing of copper and ceruloplasmin. It is not appropriate for patients with disorders of copper metabolism, such as Wilson's disease. This is a peptide that specifically calls for physician supervision.
GHK-Cu is given by subcutaneous injection in cycles, and the protocol is individualized: the figures here are a general framework, not a prescription.
Protocols commonly start around 1–2 mg daily, five days a week, for four to twelve weeks, followed by cyclical maintenance with breaks. Longer-term use includes copper and ceruloplasmin monitoring. Your dose, schedule, and cycle are set with your physician at the consult.
With any injected peptide, the source is a safety issue, not a detail. With GHK-Cu, which also delivers copper, so is the monitoring. We prescribe GHK-Cu compounded for human use by a licensed pharmacy, on a prescription, and supervise its use, including periodic copper testing.
Most peptides sold online are labeled "research use only" — not for human use — and are produced without a regulatory framework to confirm their contents, purity, or sterility.
Reported side effects of GHK-Cu are generally mild, though the injection in particular can sting or burn at the site, which is one reason local and topical routes are of interest. Human data for injectable use is limited, so the long-term safety profile is not fully established.
GHK-Cu is not an FDA-approved medication. Why "research use only" peptides are a problem →
Let's begin
Whether GHK-Cu fits your goals, at what dose and by which route, is decided in a consultation and set within a plan built around what you are trying to achieve.
That plan uses GHK-Cu on its own for a focused skin or hair goal, or as one part of a broader plan when your goals call for it.
Book a peptide consult for a targeted goal, or start with a comprehensive evaluation when you want the fuller picture first. To speak with us first, call 714-671-2005.
GLOW (BPC-157 / TB-500 / GHK-Cu) — the repair pair with GHK-Cu added
Why am I losing my hair? The causes
Why "research use only" peptides are a problem
What a comprehensive evaluation includes
As a general framework, protocols often start at 1–2 mg daily, five days a week, for four to twelve weeks, followed by cyclical maintenance with breaks. These are frameworks, not a prescription — the appropriate dose is set by your provider, and longer-term use includes copper monitoring.
Yes, hair is one of its studied applications; in laboratory research it has been associated with follicle support and effects on the pathway that produces DHT. Human evidence is limited and results vary, so we use it as part of a supervised plan rather than on its own.
Yes. GHK-Cu is used topically, and topical application with microneedling can reach higher concentrations in the skin locally than a systemic injection. The strongest human evidence for GHK-Cu is topical, and these routes are of particular interest for hair and skin.
Reported side effects are generally mild, but two points make supervision important: it delivers copper, so longer-term use requires copper monitoring and is not appropriate in copper metabolism disorders. As with any peptide, safety depends on the source.
We prescribe GHK-Cu compounded for human use through a licensed pharmacy and monitor it. Why that matters →
No. Like most peptides, injectable GHK-Cu is not an FDA-approved medication. That is precisely why prescribing, sourcing, and monitoring it through a licensed pharmacy, under a physician, matters.
